Growth Hormone-Releasing Peptide-6
Also known as: GHRP-6, Growth Hormone Releasing Peptide-6, Growth Hormone-Releasing Hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
5 notable studies · 7 references
TLDR
GHRP-6 is a synthetic ghrelin-receptor agonist with well-established growth-hormone-stimulating activity in humans and strong interactions with endogenous GHRH signaling, but long-term clinical benefits and safety for commonly promoted body-composition, recovery, and performance uses have not been established.
Research Supports
- Studied for stimulating growth hormone secretion via the ghrelin/GHS receptor
- Investigated for synergy with endogenous and administered GHRH signaling
- Studied as a provocative diagnostic test for adult growth hormone reserve
- Investigated for effects on ACTH, cortisol, and nocturnal sleep-related neuroendocrine physiology
- Studied for human pharmacokinetics and effects on metabolic/glucose regulation
Observations Reported in Research
- Blocking endogenous GHRH with an antagonist dropped peak GH response from about 33.8 to 6.2 micrograms/L (1998 study, 9 men)
- Patients with hypothalamic-pituitary disconnection showed almost complete loss of the GHRP-6 response while retaining a GHRH response (Popovic et al., 1995)
- In 349 adults, GH measured 30 minutes after combined GHRH + GHRP-6 correlated extremely strongly (r = 0.994) with the full peak response (Casanueva et al., 2002)
- In 21 adults previously diagnosed with GH deficiency, about 40% showed substantial GH responses to combined GHRH + GHRP-6 despite their prior diagnosis
- Pharmacokinetic study in 9 healthy men found unusual secondary concentration spikes during elimination in 4 of 9 participants (Cabrales et al., 2013)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic hexapeptide; growth hormone secretagogue; ghrelin/growth hormone secretagogue receptor agonist
GHRP-6 is a synthetic six-amino-acid peptide that stimulates endogenous growth hormone secretion through the growth hormone secretagogue receptor (GHS-R1a), now commonly known as the ghrelin receptor. It was developed before the discovery of ghrelin itself and became an important research tool for uncovering how growth hormone secretion is controlled outside the classical GHRH pathway. Human experiments have clearly demonstrated that GHRP-6 can stimulate GH release. Its effect is particularly strong when combined experimentally with GHRH stimulation, reflecting interaction between the two signaling systems. GHRP-6 can also influence ACTH/cortisol and other aspects of ghrelin-receptor physiology. It is therefore less appropriate to describe it as a selectively GH-specific secretagogue like ipamorelin. GHRP-6 is not FDA-approved in the United States. FDA currently identifies compounded GHRP-6 as presenting potential safety concerns involving immunogenicity, cortisol and reduced insulin sensitivity/increased blood glucose.
What Is Growth Hormone-Releasing Peptide-6?
GHRP-6 is a synthetic hexapeptide with the sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ It belongs to the growth hormone-releasing peptide family. Researchers discovered that these small synthetic peptides could stimulate powerful GH responses despite having no structural resemblance to endogenous GHRH. This suggested that another receptor system controlling GH secretion must exist. The growth hormone secretagogue receptor was subsequently identified, and in 1999 researchers discovered its endogenous ligand: ghrelin. GHRP-6 is therefore best understood as a synthetic agonist of the ghrelin/GHS receptor rather than as a GHRH analogue. Its pharmacology extends beyond GH secretion because ghrelin-receptor signaling participates in appetite, gastrointestinal physiology, energy regulation and neuroendocrine signaling.
What Are Researchers Studying?
Growth hormone secretion
Growth hormone secretion is the best-established biological effect of GHRP-6. Controlled human experiments have repeatedly demonstrated substantial increases in circulating GH following GHRP-6 administration. In one study of healthy adults, GHRP-6 produced a GH response comparable with GHRH when each was administered independently. This demonstrates human endocrine activity but does not establish long-term therapeutic benefit.
Interaction with GHRH
One of the most interesting characteristics of GHRP-6 is its interaction with endogenous and administered GHRH. When GHRP-6 and GHRH are experimentally administered together, the resulting GH response can be substantially greater than the response to either compound alone. This helped researchers establish that GHRP and GHRH signaling represent distinct but interacting components of GH regulation.
Hypothalamic regulation of growth hormone
Researchers initially debated whether GHRP-6 acted primarily at the pituitary, hypothalamus, or both. Human experiments involving patients with hypothalamic-pituitary disconnection provided important evidence. Those patients retained a response to GHRH but showed a dramatically impaired response to GHRP-6, suggesting that much of GHRP-6's effect depends upon an intact hypothalamic pathway. A later experiment using a GHRH antagonist found that blocking endogenous GHRH eliminated most of the GH response to GHRP-6.
Growth hormone deficiency and diagnostic testing
The powerful GH response produced by combined GHRH and GHRP-6 stimulation led researchers to investigate the combination as a provocative test of growth hormone reserve. In a study involving 349 adults, researchers found an extremely strong correlation between the GH concentration measured 30 minutes after GHRH + GHRP-6 stimulation and the complete peak response. The investigators concluded that the test provided a convenient method for assessing adult GH reserve. This diagnostic research should not be interpreted as evidence supporting chronic GHRP-6 administration.
ACTH and cortisol signaling
GHRP-6 does not exclusively stimulate GH. Human experiments have demonstrated increases in ACTH and cortisol under some experimental conditions. For example, repeated intravenous administration during nighttime experiments increased GH, ACTH and cortisol. This is an important distinction from ipamorelin, which was specifically developed for greater GH selectivity.
Sleep and neuroendocrine physiology
Researchers have used GHRP-6 to investigate interactions between GH-secretagogue signaling and sleep. Human experiments examined intravenous, oral, intranasal and sublingual administration and measured GH, ACTH, cortisol and sleep EEG parameters. These studies provide insight into neuroendocrine physiology but do not establish GHRP-6 as a treatment for insomnia or other sleep disorders.
Metabolic regulation
Growth hormone and ghrelin signaling both interact with glucose metabolism and insulin sensitivity. Researchers have investigated GHRP-6 responses in people with type 2 diabetes and under metabolic conditions such as fasting. FDA currently identifies reduced insulin sensitivity and resulting increases in blood glucose as potential safety concerns associated with GHRP-6.
How Does It Work?
GHRP-6 primarily activates GHS-R1a, the ghrelin receptor. This receptor is expressed within the hypothalamic-pituitary system as well as other tissues. Activation promotes growth hormone secretion through interacting mechanisms involving: • Hypothalamic signaling • Pituitary somatotroph activity • Endogenous GHRH • Somatostatin regulation • Ghrelin-receptor signaling Human experiments provide particularly strong evidence that endogenous GHRH is involved. When researchers administered a GHRH antagonist to healthy men before GHRP-6, most of the normal GH response disappeared. Peak GH increase fell from approximately 33.8 μg/L to 6.2 μg/L. This helps explain why GHRP-6 and GHRH stimulation can interact synergistically. Mechanistically: CJC-1295 / Tesamorelin → GHRH receptor GHRP-6 / GHRP-2 / Ipamorelin → GHS-R1a / ghrelin receptor The pathways are distinct but functionally interconnected.
What Does the Research Show?
Human research
GHRP-6 has considerably more direct human research than many compounds discussed in research-peptide communities. Human studies have demonstrated: • Acute GH stimulation • Synergy with GHRH • Dependence on endogenous hypothalamic/GHRH signaling • Effects on ACTH and cortisol • Responses in growth hormone deficiency • Responses in metabolic disease • Pharmacokinetics • Potential utility in provocative endocrine testing For example, 21 adults previously diagnosed with GH deficiency received combined GHRH and GHRP-6. Approximately 40% demonstrated substantial GH responses despite their previous diagnosis based on conventional testing. Another study involving 349 adults evaluated GHRH + GHRP-6 as a diagnostic test of GH reserve. A Phase I pharmacokinetic study subsequently administered GHRP-6 intravenously to nine healthy male volunteers and characterized its disposition in humans. These experiments establish that GHRP-6 is pharmacologically active in humans. They do not establish that repeated administration improves muscle growth, fat loss, athletic performance, injury recovery or longevity.
Animal research
Animal research has investigated GHRP-6 extensively. Areas studied include: • GH secretion • Hypothalamic signaling • Pituitary signaling • Appetite • Gastrointestinal function • Cardiovascular injury • Tissue protection • Metabolic regulation Animal studies were particularly important before the discovery of ghrelin because they helped establish that synthetic GHRPs acted through a regulatory pathway distinct from GHRH. These experiments remain useful for mechanistic research but cannot establish human therapeutic outcomes.
In-vitro research
Cellular experiments have examined GHRP-6 interactions with the growth hormone secretagogue receptor and downstream intracellular signaling. Research has also investigated effects on pituitary cells, hypothalamic signaling and receptor desensitization. The presence of the unnatural D-amino acids in GHRP-6 contributes to its resistance to ordinary peptide degradation but also makes pharmaceutical characterization more complex. In-vitro receptor activity establishes mechanism, not clinical effectiveness.
Notable Studies
Effect of Growth Hormone (GH)-Releasing Hormone, Atropine, Pyridostigmine, or Hypoglycemia on GHRP-6-Induced GH Secretion in Man
humanResearchers investigated GHRP-6 alone and under several conditions designed to alter GHRH and somatostatin signaling. In healthy participants, GHRP-6 and GHRH individually produced broadly similar increases in plasma GH. The experiments helped demonstrate that GHRP-6's action interacts strongly with the normal hypothalamic regulation of GH secretion.
Limitations: This was an acute physiological experiment rather than a therapeutic trial. It measured hormone responses rather than clinical outcomes.
View publication →Blocked Growth Hormone-Releasing Peptide (GHRP-6)-Induced GH Secretion and Absence of the Synergic Action of GHRP-6 Plus GH-Releasing Hormone in Patients With Hypothalamopituitary Disconnection
humanResearchers compared GHRH, GHRP-6 and combined GHRH + GHRP-6 in 12 patients with hypothalamic-pituitary disconnection and 11 controls. Controls demonstrated a strong GHRP-6 response and pronounced synergy when GHRP-6 and GHRH were combined. Patients with hypothalamic-pituitary disconnection retained a response to GHRH but showed almost complete loss of the GHRP-6 response. The findings provided strong evidence that a major component of GHRP-6 activity occurs through hypothalamic signaling.
Limitations: The study was small and designed to understand mechanism rather than therapeutic effectiveness.
View publication →Growth Hormone (GH)-Releasing Peptide-6 Requires Endogenous Hypothalamic GH-Releasing Hormone for Maximal GH Stimulation
humanNine healthy men received GHRP-6 either normally or following administration of a GHRH antagonist. Blocking endogenous GHRH eliminated most of the GH response to GHRP-6. Peak GH increase fell from approximately 33.8 μg/L under control conditions to 6.2 μg/L after GHRH blockade. The study demonstrated that endogenous GHRH is necessary for most of GHRP-6's maximal GH-stimulating effect in humans.
Limitations: Only nine healthy young men participated. The study evaluated acute hormone physiology rather than clinical outcomes or long-term safety.
View publication →A Single Growth Hormone Determination Is Sufficient for the Diagnosis of GH Deficiency in Adult Patients Using the Growth Hormone-Releasing Hormone Plus Growth Hormone-Releasing Peptide-6 Test
humanResearchers studied 349 adults, including 146 people with organic pituitary disease and 203 healthy controls. All participants received combined GHRH + GHRP-6 stimulation. GH measured at 30 minutes correlated extremely strongly with the complete peak response (r = 0.994). Researchers concluded that a simplified 30-minute measurement could provide reliable classification during this provocative test.
Limitations: This was diagnostic research. It does not establish benefits from chronic administration of either GHRP-6 or the combination.
View publication →Pharmacokinetic Study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in Nine Male Healthy Volunteers
humanResearchers administered a single intravenous GHRP-6 exposure to nine healthy male volunteers and measured circulating peptide concentrations. The study directly characterized human GHRP-6 pharmacokinetics and confirmed systemic exposure following intravenous administration. Researchers also observed unusual secondary concentration spikes during the elimination phase in four of the nine participants.
Limitations: Only nine healthy male volunteers participated. The experiment examined pharmacokinetics rather than long-term safety or clinical efficacy.
View publication →What We Still Don't Know
Important unresolved questions include: • Whether chronic GHRP-6 exposure produces clinically meaningful improvements in body composition • Whether it increases muscle strength or functional performance • Whether it improves exercise or injury recovery • Long-term cardiovascular safety • Long-term effects on glucose regulation • Clinical significance of reduced insulin sensitivity • Consequences of repeated ACTH/cortisol stimulation • Long-term effects of GH/IGF-1 elevation • Immunogenicity after repeated exposure • Effects of aggregation and peptide-related impurities • Whether chronic ghrelin-receptor stimulation produces meaningful changes in appetite or energy balance • Safety and efficacy of commonly marketed formulations • Whether preclinical tissue-protective findings translate into human outcomes FDA specifically identifies limited safety information for GHRP-6 and notes potential effects on cortisol and blood glucose resulting from decreased insulin sensitivity.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Growth Hormone-Releasing Peptide-6 research with you.
Get the Aminodex Growth Hormone-Releasing Peptide-6 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Peñalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C. Effect of Growth Hormone-Releasing Hormone, Atropine, Pyridostigmine, or Hypoglycemia on GHRP-6-Induced GH Secretion in Man. Journal of Clinical Endocrinology & Metabolism. 1993;76(1).
- Popovic V, Damjanovic S, Micic D, et al. Blocked Growth Hormone-Releasing Peptide (GHRP-6)-Induced GH Secretion and Absence of the Synergic Action of GHRP-6 Plus GH-Releasing Hormone in Patients With Hypothalamopituitary Disconnection. Journal of Clinical Endocrinology & Metabolism. 1995;80(3).
- Growth Hormone-Releasing Peptide-6 Requires Endogenous Hypothalamic GH-Releasing Hormone for Maximal GH Stimulation. Journal of Clinical Endocrinology & Metabolism. 1998;83(4).
- Frieboes RM, Murck H, Antonijevic IA, Steiger A. Effects of Growth Hormone-Releasing Peptide-6 on the Nocturnal Secretion of GH, ACTH and Cortisol and on the Sleep EEG in Man: Role of Routes of Administration. Journal of Neuroendocrinology. 1999.
- A Single Growth Hormone Determination Is Sufficient for the Diagnosis of GH-Deficiency in Adult Patients Using the Growth Hormone-Releasing Hormone Plus Growth Hormone-Releasing Peptide-6 Test. 2002.
- Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic Study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in Nine Male Healthy Volunteers. European Journal of Pharmaceutical Sciences. 2013;48(1-2):40–46. doi:10.1016/j.ejps.2012.10.006.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks: Growth Hormone Releasing Peptide-6.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.